Upgrades
For Avidity Biosciences Inc (NASDAQ:RNA), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. In the first quarter, Avidity Biosciences showed an EPS of $0.74, compared to $0.71 from the year-ago quarter. The current stock performance of Avidity Biosciences shows a 52-week-high of $25.74 and a 52-week-low of $9.88. Moreover, at the end of the last trading period, the closing price was at $10.82.
Odeon Capital upgraded the previous rating for KeyCorp (NYSE:KEY) from Hold to Buy. For the first quarter, KeyCorp had an EPS of $0.30, compared to year-ago quarter EPS of $0.45. The stock has a 52-week-high of $20.30 and a 52-week-low of $8.54. At the end of the last trading period, KeyCorp closed at $9.82.
Argus Research upgraded the previous rating for Rocket Companies Inc (NYSE:RKT) from Sell to Hold. For the first quarter, Rocket Companies had an EPS of $0.06, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $11.38 and a 52-week-low of $5.97. Rocket Companies closed at $8.16 at the end of the last trading period.
According to Vertical Research, the prior rating for Corteva Inc (NYSE:CTVA) was changed from Hold to Buy. Corteva earned $1.16 in the first quarter, compared to $0.97 in the year-ago quarter. The current stock performance of Corteva shows a 52-week-high of $68.42 and a 52-week-low of $50.03. Moreover, at the end of the last trading period, the closing price was at $56.97.
Citigroup upgraded the previous rating for Knight-Swift Transportation Holdings Inc (NYSE:KNX) from Neutral to Buy. For the first quarter, Knight-Swift had an EPS of $0.73, compared to year-ago quarter EPS of $1.35. At the moment, the stock has a 52-week-high of $64.35 and a 52-week-low of $43.15. Knight-Swift closed at $54.59 at the end of the last trading period.
BMO Capital upgraded the previous rating for TrueBlue Inc (NYSE:TBI) from Market Perform to Outperform. TrueBlue earned $0.06 in the first quarter, compared to $0.44 in the year-ago quarter. The stock has a 52-week-high of $23.00 and a 52-week-low of $14.20. At the end of the last trading period, TrueBlue closed at $16.04.
For Azul SA (NYSE:AZUL), B of A Securities upgraded the previous rating of Underperform to Neutral. For the first quarter, Azul had an EPS of $0.99, compared to year-ago quarter EPS of $1.14. The current stock performance of Azul shows a 52-week-high of $13.81 and a 52-week-low of $3.82. Moreover, at the end of the last trading period, the closing price was at $8.40.
For Norfolk Southern Corp (NYSE:NSC), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, Norfolk Southern had an EPS of $3.32, compared to year-ago quarter EPS of $2.93. The stock has a 52-week-high of $264.17 and a 52-week-low of $196.33. At the end of the last trading period, Norfolk Southern closed at $217.74.
According to Citigroup, the prior rating for Norfolk Southern Corp (NYSE:NSC) was changed from Neutral to Buy. For the first quarter, Norfolk Southern had an EPS of $3.32, compared to year-ago quarter EPS of $2.93. At the moment, the stock has a 52-week-high of $264.17 and a 52-week-low of $196.33. Norfolk Southern closed at $217.74 at the end of the last trading period.
For Union Pacific Corp (NYSE:UNP), Citigroup upgraded the previous rating of Neutral to Buy. In the first quarter, Union Pacific showed an EPS of $2.54, compared to $2.57 from the year-ago quarter. The current stock performance of Union Pacific shows a 52-week-high of $242.35 and a 52-week-low of $183.69. Moreover, at the end of the last trading period, the closing price was at $198.97.
UBS upgraded the previous rating for DraftKings Inc (NASDAQ:DKNG) from Neutral to Buy. In the first quarter, DraftKings showed an EPS of $0.87, compared to $1.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.34 and a 52-week-low of $10.52. DraftKings closed at $24.11 at the end of the last trading period.
According to JP Morgan, the prior rating for AnaptysBio Inc (NASDAQ:ANAB) was changed from Underweight to Neutral. For the first quarter, AnaptysBio had an EPS of $1.58, compared to year-ago quarter EPS of $1.31. The stock has ...Full story available on Benzinga.com
Benzinga
